S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Turkey’s central bank hikes interest rates again in further shift in economic policies
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Turkey’s central bank hikes interest rates again in further shift in economic policies
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Turkey’s central bank hikes interest rates again in further shift in economic policies
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Turkey’s central bank hikes interest rates again in further shift in economic policies
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Forecast, Price & News

$1.12
+0.02 (+1.82%)
(As of 09/21/2023 ET)
Compare
Today's Range
$1.06
$1.13
50-Day Range
$1.07
$1.38
52-Week Range
$0.67
$2.04
Volume
786,081 shs
Average Volume
847,085 shs
Market Capitalization
$195.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75

Rigel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
413.4% Upside
$5.75 Price Target
Short Interest
Healthy
2.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.26) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

729th out of 965 stocks

Pharmaceutical Preparations Industry

340th out of 453 stocks


RIGL stock logo

About Rigel Pharmaceuticals (NASDAQ:RIGL) Stock

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

RIGL Price History

RIGL Stock News Headlines

Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Q2 2023 Rigel Pharmaceuticals Inc Earnings Call
Rigel Pharmaceuticals Inc. Q2 Loss decreases, beats estimates
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Q1 2023 Rigel Pharmaceuticals Inc Earnings Call
Rigel Pharmaceuticals Inc. Q1 Loss decreases, beats estimates
12 Best Low-Priced Growth Stocks To Buy
See More Headlines
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Company Calendar

Last Earnings
8/01/2023
Today
9/21/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RIGL
CUSIP
76655960
Employees
155
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$5.75
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+413.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-58,570,000.00
Pretax Margin
-29.83%

Debt

Sales & Book Value

Annual Sales
$120.24 million
Book Value
($0.08) per share

Miscellaneous

Free Float
159,717,000
Market Cap
$195.28 million
Optionable
Optionable
Beta
0.69

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Raul R. Rodriguez (Age 62)
    Pres, CEO & Director
    Comp: $1.09M
  • Mr. Dean L. Schorno CPA (Age 60)
    Exec. VP & CFO
    Comp: $696.67k
  • Mr. Raymond J. Furey J.D. (Age 55)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $593.46k
  • Mr. David A. Santos (Age 60)
    Exec. VP & Chief Commercial Officer
    Comp: $681.63k
  • Mr. Joseph Lasaga (Age 48)
    Exec. VP of Corp. Devel.
  • Ms. Julie Patel
    Sr. VP of HR
  • Dr. Esteban S. Masuda (Age 61)
    Exec. VP of Research
  • Mr. Tarek Sallam
    VP of Marketing













RIGL Stock - Frequently Asked Questions

Should I buy or sell Rigel Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RIGL shares.
View RIGL analyst ratings
or view top-rated stocks.

What is Rigel Pharmaceuticals' stock price forecast for 2023?

4 equities research analysts have issued 12 month price targets for Rigel Pharmaceuticals' stock. Their RIGL share price forecasts range from $2.00 to $15.00. On average, they expect the company's stock price to reach $5.75 in the next year. This suggests a possible upside of 413.4% from the stock's current price.
View analysts price targets for RIGL
or view top-rated stocks among Wall Street analysts.

How have RIGL shares performed in 2023?

Rigel Pharmaceuticals' stock was trading at $1.50 at the start of the year. Since then, RIGL stock has decreased by 25.3% and is now trading at $1.12.
View the best growth stocks for 2023 here
.

When is Rigel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RIGL earnings forecast
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its earnings results on Tuesday, August, 1st. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. The biotechnology company had revenue of $26.89 million for the quarter, compared to the consensus estimate of $26.02 million. During the same quarter in the previous year, the company earned ($0.08) earnings per share.

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.38%), Acadian Asset Management LLC (2.63%), Assenagon Asset Management S.A. (2.09%), State Street Corp (2.02%), Geode Capital Management LLC (1.95%) and Nuveen Asset Management LLC (1.41%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez.
View institutional ownership trends
.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $1.12.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $195.28 million and generates $120.24 million in revenue each year. The biotechnology company earns $-58,570,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

The company employs 155 workers across the globe.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101.

This page (NASDAQ:RIGL) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -